Use of positron emission tomography (PET/CT) is relatively recent in Brazil and has not yet been incorporated to reimbursement procedures tables of the public health system (SUS). Lung cancer represents 7.1% of non-melanoma cancers occurring in Brazil in 2012. PET-CT with radiolabeled [ 18 F]-2-fluoro-deoxy-D-glucose (FDG) has become a widely used technology for preoperative staging of non-small cell lung cancer (NSCLC). Accurate evaluation is essential to confirm the diagnosis and preoperatively detect mediastinal lymph node involvement and distant metastasis, avoiding non-curative surgery that impact on morbidity, mortality and costs.
The purpose of this study was to determine a cost-effectiveness of utilization of PET-CT in staging NSCLC to avoid non-curative surgeries.
A decision tree model was developed with four work-up approaches: (i) CT alone, (ii) PET/CT for all, (iii) PET/CT when negative CT, and (iv) mediastinoscopy only in CT+ or PET/CT+ (Figure 1 ). Mediastinoscopy was included in all alternatives to confirm positive CT or PET/CT results. Surgery was considered non-curative (i.e, unnecessary) when the workup drives to resectable stage but the model predicts locoregional or distant metastasis. The model incorporated evidence-based data from the literature and associated costs were evaluated from the Brazilian public health care system perspective. All direct medical costs of preoperative staging with 18 FDG-PET/CT and conventional methods were considered, as well the costs of medical care considering the outcomes. The costs of PET/CT in Brazil were estimated in previous study by microcosts technique. Year 2012 American dollars was used as the currency. The parameters used in reference case and sensitivity analysis are in Table 1 . The impact of uncertainties on the model was verified by deterministic and probabilistic sensitivity analyses (PSA). Cost-effectiveness acceptability curves was estimated. Brazil does not have willingness-to-pay threshold for cost-effective technology. Figure 1: Decision tree outline of four strategies analyzed.
A diamond represents continuation to the designated strategy.
Although PET/CT is recommended for staging potential resectable lung cancer patients, the procedure is not reimbursed in Brazilian public health care system yet. Our study shows that include PET/CT in the work-up staging of lung cancer could prevent misleading surgeries due to undiagnosed advanced disease. In term of cost-effectiveness, PET/CT in negative CT patients is the most cost-effective strategy with a probability higher than 90% when the willingness-to-pay is US$10.000,00 superior. Table 2 ). The strategy PET/CT for all was dominated. In sensitivity analysis, estimates of ICER were sensitive to changes in the probability of distant metastasis, the cost of PET/CT procedure and probability of N2/3 disease (Figure 2) . PET-CT restricted utilization in patients with normal mediastinal nodes at CT is a cost-effective strategy, with a probability of 90% if willigness-topay value was inferior than U$10,000.00. 
